Last reviewed · How we verify
Tirofiban Injection
At a glance
| Generic name | Tirofiban Injection |
|---|---|
| Also known as | Ibisqus, Agrastat |
| Sponsor | University of Milan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (PHASE4)
- One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China (PHASE2)
- A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke (PHASE2)
- Tirofiban for Patients Treated With Alteplase (PHASE2, PHASE3)
- Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 (PHASE2)
- Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tirofiban Injection CI brief — competitive landscape report
- Tirofiban Injection updates RSS · CI watch RSS
- University of Milan portfolio CI